MTOR and breast carcinoma: Our analysis revealed that the b-Raf-ERK1/2-mTOR pathway is activated in the breast cancer patient samples as well as in the tumor cells cultured on Matrigel with high LMW-E expression (Figure 5B and 5C and Table S3).